These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 32929554)

  • 1. Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma.
    Schuiveling M; Tonk EHJ; Verheijden RJ; Suijkerbuijk KPM
    Cancer Immunol Immunother; 2021 May; 70(5):1491-1496. PubMed ID: 32929554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
    Denis M; Duruisseaux M; Brevet M; Dumontet C
    Front Immunol; 2020; 11():492. PubMed ID: 32265935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperprogression after nivolumab for melanoma: A case report.
    Yilmaz M; Akovali B
    J Oncol Pharm Pract; 2020 Jan; 26(1):244-251. PubMed ID: 31068087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
    Adashek JJ; Kato S; Ferrara R; Lo Russo G; Kurzrock R
    Oncologist; 2020 Feb; 25(2):94-98. PubMed ID: 32043794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature.
    Feng D; Guan Y; Liu M; He S; Zhao W; Yin B; Liang J; Li Y; Wang J
    Front Immunol; 2021; 12():608292. PubMed ID: 34135884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.
    Matos I; Martin-Liberal J; García-Ruiz A; Hierro C; Ochoa de Olza M; Viaplana C; Azaro A; Vieito M; Braña I; Mur G; Ros J; Mateos J; Villacampa G; Berché R; Oliveira M; Alsina M; Elez E; Oaknin A; Muñoz-Couselo E; Carles J; Felip E; Rodón J; Tabernero J; Dienstmann R; Perez-Lopez R; Garralda E
    Clin Cancer Res; 2020 Apr; 26(8):1846-1855. PubMed ID: 31757877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Solid Tumor Treatment Response Observed in Clinical Practice With Response Reported in Clinical Trials.
    Feinberg BA; Zettler ME; Klink AJ; Lee CH; Gajra A; Kish JK
    JAMA Netw Open; 2021 Feb; 4(2):e2036741. PubMed ID: 33630085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors.
    Faure M; Rochigneux P; Olive D; Taix S; Brenot-Rossi I; Gilabert M
    Front Immunol; 2018; 9():797. PubMed ID: 29725330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade.
    Bello DM; Panageas KS; Hollmann T; Shoushtari AN; Momtaz P; Chapman PB; Postow MA; Callahan MK; Wolchok JD; Brady MS; Coit DG; Ariyan CE
    Ann Surg Oncol; 2020 Apr; 27(4):1180-1188. PubMed ID: 31848819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atypical response patterns in metastatic melanoma and renal cell carcinoma patients treated with nivolumab: A single center experience.
    Yilmaz M
    J Oncol Pharm Pract; 2021 Jul; 27(5):1106-1111. PubMed ID: 32799776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case Report: Simultaneous Hyperprogression and Fulminant Myocarditis in a Patient With Advanced Melanoma Following Treatment With Immune Checkpoint Inhibitor Therapy.
    Barham W; Guo R; Park SS; Herrmann J; Dong H; Yan Y
    Front Immunol; 2020; 11():561083. PubMed ID: 33603731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors.
    Gabryś HS; Basler L; Burgermeister S; Hogan S; Ahmadsei M; Pavic M; Bogowicz M; Vuong D; Tanadini-Lang S; Förster R; Kudura K; Huellner M; Dummer R; Levesque MP; Guckenberger M
    Front Oncol; 2022; 12():977822. PubMed ID: 36505821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperprogressive disease: A distinct pattern of progression to immune checkpoint inhibitors.
    Toki MI; Syrigos N; Syrigos K
    Int J Cancer; 2021 Jul; 149(2):277-286. PubMed ID: 33300601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint inhibitor use: a case series.
    Wong DJ; Lee J; Choo SP; Thng CH; Hennedige T
    Immunotherapy; 2019 Feb; 11(3):167-175. PubMed ID: 30730278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma.
    Forschner A; Hilke FJ; Bonzheim I; Gschwind A; Demidov G; Amaral T; Ossowski S; Riess O; Schroeder C; Martus P; Klumpp B; Gonzalez-Menendez I; Garbe C; Niessner H; Sinnberg T
    Cancers (Basel); 2020 Feb; 12(3):. PubMed ID: 32110946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personal response to immune checkpoint inhibitors of patients with advanced melanoma explained by a computational model of cellular immunity, tumor growth, and drug.
    Perlstein D; Shlagman O; Kogan Y; Halevi-Tobias K; Yakobson A; Lazarev I; Agur Z
    PLoS One; 2019; 14(12):e0226869. PubMed ID: 31877168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma.
    Lacal PM; Atzori MG; Ruffini F; Scimeca M; Bonanno E; Cicconi R; Mattei M; Bernardini R; D'Atri S; Tentori L; Graziani G
    Pharmacol Res; 2020 Sep; 159():104957. PubMed ID: 32485280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune-checkpoint inhibitors in renal transplanted patients affected by melanoma: a systematic review.
    Rossi E; Schinzari G; Maiorano BA; Esposito I; Acampora A; Romagnoli J; Stefani AD; Regno LD; Lancellotta V; Fionda B; Tagliaferri L; Peris K; Tortora G
    Immunotherapy; 2022 Jan; 14(1):65-75. PubMed ID: 34751039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma.
    Bastholt L; Schmidt H; Bjerregaard JK; Herrstedt J; Svane IM
    Eur J Cancer; 2019 Sep; 119():122-131. PubMed ID: 31442816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.
    Hwang I; Park I; Yoon SK; Lee JL
    Clin Genitourin Cancer; 2020 Apr; 18(2):e122-e133. PubMed ID: 31837940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.